PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.
PWRM's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).
PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig's disease), Alzheimer's, Parkinson's diseases, breast cancer, and drug resistance.
The NuroPro Blood Test is PWRM's diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease .
PWRM's BC-SeraPro(TM) is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient's serum sample is compared to PWRM's patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis. Probability score is ranged from 0.0 to 1.0. Results of PWRM's BC-SeraPro(TM) test should not be considered a stand alone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer's disease (NuroPro-AD), Parkinson's disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA.
More about PWRM at www.power3medical.com
SFNC, Simmons First National Corporation
SFNC, through its subsidiaries, provides a range of banking products and services to individual and corporate customers primarily in Arkansas.
** SFNC's Board of Directors declared a regular $0.19 per share quarterly cash dividend payable October 1, 2010, to shareholders of record September 15, 2010.
More about SFNC at www.simmonsfirst.com
OIS, Oil States International Inc.
OIS, through its subsidiaries, provides specialty products and services to the oil and gas drilling and production companies worldwide.
** OIS' Board of Directors has authorized $100,000,000 for the repurchase of the Company's Common Stock, par value $.01 per share.
This authorization replaces the prior share repurchase authorization which expired on December 31, 2009. OIS presently has approximately 50.2 million shares of Common Stock outstanding. The repurchases may be effected from time to time in accordance with applicable securities laws, through solicited or unsolicited transactions in the market or in privately negotiated transactions.
The Board of Directors' authorization is limited in duration and expires on September 1, 2012. Subject to applicable securities laws, such purchases will be at times and in amounts as the Company deems appropriate.
More about OIS at www.oilstatesintl.com
Sign up for free stock alerts at http://www.pennygovernance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(read more @ http://pennygovernance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)